Caribou Biosciences, Inc. (CRBU)
Caribou Biosciences, Inc. (CRBU)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Licensing and other third-party revenue | 2,397 | 3,941 | 2,198 | NaN |
| External costs | 10,690 | 14,445 | 12,285 | NaN |
| Internal costs | 8,179 | 7,612 | 8,364 | NaN |
| Total research and development | 18,869 | 22,057 | 20,649 | NaN |
| General and administrative | 6,802 | 6,916 | 7,389 | NaN |
| Other segment items | 3,006 | 3,656 | 3,560 | NaN |
| Other income, net | 1,195 | 2,200 | 11,402 | NaN |
| Net loss | -25,085 | -26,488 | -27,548 | -94,089 |
| Depreciation and amortization | 649 | 682 | 631 | 2,332 |
| Gain on disposal of fixed assets | NaN | 0 | 0 | 25 |
| Non-cash consideration for licensing and collaboration revenue | NaN | 0 | 0 | 9 |
| Impairment charges | NaN | 0 | 0 | 12,150 |
| Change in fair value of equity securities | 0 | -115 | 12 | 4 |
| Impairment of equity method investment | NaN | 0 | 0 | -9,158 |
| Stock-based compensation expense | 2,357 | 2,738 | 2,931 | 7,011 |
| Change in fair value of the mskcc success payments liability | 0 | 0 | 0 | -785 |
| Acquired in-process research and development | NaN | 0 | 0 | 0 |
| Accretion of discounts on investments in marketable securities, net | 269 | 160 | 235 | 745 |
| Non-cash lease expense | 315 | 422 | 457 | 965 |
| Accounts receivable | 158 | -173 | 171 | -194 |
| Contract assets | -315 | 146 | 107 | -405 |
| Other receivables | -459 | 76 | -129 | 129 |
| Prepaid expenses and other current assets | -522 | -2,403 | -461 | -811 |
| Other assets | -63 | -1,609 | 155 | -1,896 |
| Accounts payable | -2,220 | 1,919 | 561 | 774 |
| Accrued expenses and other current liabilities | -2,646 | -2,816 | -1,111 | -2,413 |
| Deferred revenue, current and long-term | -1,005 | -326 | -627 | -1,845 |
| Operating lease liabilities | -281 | -325 | -389 | -635 |
| Deferred tax liabilities | NaN | -548 | NaN | NaN |
| Net cash used in operating activities | -26,984 | -20,824 | -25,185 | -64,983 |
| Proceeds from maturities of marketable securities | 46,142 | 61,788 | 68,414 | 122,628 |
| Purchases of marketable securities | 22,085 | 44,034 | 57,448 | 47,751 |
| Purchases of property and equipment | 72 | -216 | 115 | 1,460 |
| Proceeds from sale of property and equipment | NaN | 0 | NaN | NaN |
| Payments to acquire in-process research and development | NaN | 0 | 0 | 0 |
| Net cash provided by investing activities | 23,985 | 17,970 | 10,851 | 73,417 |
| Proceeds from exercise of stock options | 9 | 0 | 0 | 6 |
| Proceeds from issuances of common stock under espp | 468 | 0 | 277 | 468 |
| Proceeds from issuances of common stock related to atm, net of offering expenses | 2,219 | 4,070 | 0 | 0 |
| Net cash provided by financing activities | 2,696 | 4,070 | 277 | 474 |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | -303 | 1,216 | -14,057 | 8,908 |
| Cash, cash equivalents, and restricted cash beginning of period | 12,406 | 11,190 | 16,339 | NaN |
| Cash, cash equivalents, and restricted cash end of period | 12,103 | 12,406 | 11,190 | NaN |